BELIMUMAB AFTER RITUXIMAB SIGNIFICANTLY REDUCED IGG ANTI-DSDNA ANTIBODY LEVELS AND PROLONGED TIME TO SEVERE FLARE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

被引：5

作者：

Shipa, M. ^{[1
]}

Embleton-Thirsk, A. ^{[2
]}

Parvaz, M. ^{[1
]}

Ribeiro, L. Santos ^{[1
]}

Muller, P. ^{[2
]}

Chowdhury, K. ^{[2
]}

Isenberg, D. ^{[1
]}

Dore, C. ^{[2
]}

Gordon, C. ^{[3
]}

Ehrenstein, M. ^{[1
]}

机构：

[1] UCL, Dept Rheumatol, London, England

[2] UCL, Comprehens Clin Trials Unit, London, England

[3] Univ Birmingham, Rheumatol Res Team Inflammat & Ageing, Birmingham, W Midlands, England

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷

关键词：

D O I：

10.1136/annrheumdis-2021-eular.553

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0129

引用

页码：74 / 74

页数：1

共 2 条

[1] Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial [J].

Jones, Alexis ;

Muller, Patrick ;

Dore, Caroline J. ;

Ikeji, Felicia ;

Caverly, Emilia ;

Chowdhury, Kashfia ;

Isenberg, David A. ;

Gordon, Caroline ;

Ehrenstein, Michael R. .

BMJ OPEN, 2019, 9 (12)

[2] Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan [J].

Muller, Patrick ;

Chowdhury, Kashfia ;

Gordon, Caroline ;

Ehrenstein, Michael R. ;

Dore, Caroline J. .

TRIALS, 2020, 21 (01)

← 1 →